Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea
NCT05944965Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine and oxybutynin in obstructive sleep apnea (OSA) (3 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Peak Genioglossus Activity, Tensor Palatini Activity and 1 more. Started Dec 2023; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05944965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05944965.